GlassScriptPhysician profile
Mihail Medvedovsky
NPI 1962408880
$4,200.65
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $188 · 2021: $277 · 2022: $66.68 · 2023: $107 · 2024: $3,224 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $3,167 · Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $3,167.06 |
| Food and Beverage | $329.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $3,167.06 | 2024 | |
| Abbvie INC. | $349.49 | 2019-2025 | |
| Abbott Laboratories | $263.40 | 2021 | |
| Novo Nordisk INC | $113.63 | 2025 | Ozempic |
| Shield Therapeutics INC | $69.06 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $54.63 | 2019-2020 | |
| Exact Sciences Corporation | $41.23 | 2023-2024 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $35.27 | 2024 | Zio Xt Patch, Zio Monitor |
| Lilly USA, LLC | $28.64 | 2019-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $23.86 | 2020 | |
| Glaxosmithkline, LLC. | $17.97 | 2020 | |
| Qorumpartners | $13.86 | 2022 | |
| Merck Sharp & Dohme LLC | $13.02 | 2022 | |
| Coala Life INC | $9.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihail Medvedovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.